Therapy wit antipsychotic drugs as a risk factor for diabetes in schizophrenia: A case-control study;Evaluación del tratamiento antipsicótico como factor de riesgo de diabetes en la esquizofrenia: Estudio de casos y controles

Medicina Clinica

Volumn 126, Issue 12, 2006, Pages 441-444

  Rubio, Gabriel ^a   Gómez De La Cámara, Agustín ^b   Ledesma, Francisco ^c   Burón, José A ^c   Rodríguez Morales, Alexander ^c   Martínez Junquera, Guadalupe ^c,d  

^a Centro de Salud Mental de Salamanca   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Polígono Industrial   (Spain)

^d NONE   (Spain)

Author keywords

Antipsychotics; Clozapine; Diabetes mellitus; Hipercholesterolemia; Hyperglycemia; Hyperlipidemia; Olanzapine; Risperidone; Schizophrenia; Triglycerides

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; LIPID METABOLISM; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RISK FACTOR; SCHIZOPHRENIA;

EID: 33646271984     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086323     Document Type: Article

References (30)

1. Marder SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994; 151:825-35.
2. Z. Peuskens J, and The Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-Group Study Versus Haloperidol. Br J Psychiatry. 1995;166:712-26.
3. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry. 2001;158:765-74.
4. National Institute for Clinical Excellence (NICE, NHS). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care (December 2002) [citado 19 En 2004]. Disponible en: http://www. nice.org.uk/
5. Csernansky JG, Mahmoud R, Brenner R and The Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
6. Margetic B, Aukst-Margetic B, Badanjak A. Diabetes and hyperlipidemia associated with clozapine resolved by switching to risperidone. Psychiatria Danubina. 2002;14:225-32.
7. Goldstein LE, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey GK, et al. New onset diabetes mellitus and diabetic keto-acidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438-43.
8. Iqbal N, Oldan RL, Baird G, Schwartz BJ, Bloy L, Bhagoji B, et al. Atypical antipsychotic-induced diabetes mellitus. Presentation at the 153RD Annual Meeting of the American Psychiatric Association. Chicago, 13-18 de mayo de 2000.
9. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes. Biol Psychiatry. 2001;50:148-9.
10. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry. 1999;60:556-7.
11. Haupt DW, Newcomwer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62 Suppl 27:15-26.
12. Caro JJ, Ward A, Levinton, Robinson K. The risk of diabetes during olanzapine use compared with risperiedone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-9.
13. American Diabetes Association (ADA). Screening for diabetes. Diabetes Care. 2002;25 Suppl 1:S21-4.
14. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol. 2001;11:25-32.
15. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-24.
16. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry. 2001;62 Suppl 27:27-34.
17. Baptista T, Kin N, Beaulieu, De Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35:205-19.
18. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-9.
19. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry. 2001;62 Suppl 27:10-14.
20. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 1999;60:783-91.
21. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002; 22:841-52.
22. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001; 111:716-23.
23. Koro CE, Fedder DO, L'Italien G, Weiss S, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risck of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
24. Koro CE, Fedder DO, L'Italien G, Weiss S, Magder LS, Kreyenbuhl J, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59:1021-6.
25. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-30.
26. Sernyak MJ, Leslie DI, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-6.
27. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856-65.
28. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002; 63:425-33.
29. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP. Changes in glucose and cholesterol levels in patients with schizohrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-6.
30. Newcomer JW. Metabolic disturbances associated with antipsychotic use. J Clin Psychiatry. 2001;62 Suppl 27:3-4; discussion 40-1.